Baseline characteristics of patients recruited to the mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH) trial.
Kailash Krishnan, Emma Grace, Lisa Woodhouse, Christine Roffe, Jesse Dawson, Timothy J England, David W Hewson, Rob A Dineen, Zhe Kang Law, Stefan Pszczolkowski, Keenan Wells, Amanda Buck, Jennifer Craig, Diane Havard, Mary J Macleod, David J Werring, Fergus N Doubal, Nikola Sprigg, Philip M Bath
Clin Neurol Neurosurg 264 109342
摘要
摘要
BACKGROUND: Mannitol, an osmotic diuretic and free radical scavenger might decrease cerebral oedema after acute intracerebral haemorrhage. AIMS: The Mannitol for cerebral oedema after acute intracerebral haemorrhage trial is testing the feasibility of performing a phase II trial to define the optimal approach for a phase III trial of testing mannitol in patients with cerebral oedema or at risk of it to improve outcome. METHODS: MACE-ICH is a multicentre, prospective, randomised, open-label, blinded-endpoint outcome assessment trial. Participants presenting within 72 h of ictus were randomised to one of three groups: 1:1 g/kg 10 % single dose mannitol infusion at 10 ml/min, in addition to standard care; 1 g/kg 10 % mannitol at 10 ml/min followed by a second dose 1 g/kg repeated 24 h later (providing serum osmolality <320 mOsm/Kg and sodium<160 mmol/L), in addition to standard care or standard care alone. The trial was registered prospectively: ISRCTN15383301. RESULTS: 46 (of planned 45) participants were recruited from 8 sites between February 2024-April 2025. Baseline characteristics: mean age 74.7 years (standard deviation 12.0); male 69 %; onset-to-randomisation 22.9 h; severity (National Institutes of Health Stroke Scale) 12.1 (8.3); blood pressure 155.3 (29.0)/78.9 (16.5) mmHg. Haematoma characteristics: lobar 58 %, mass effect 58.7 %, midline shift (34.8 %). The mean maximum haemorrhage diameter was 4.3 cm. CONCLUSION: MACE-ICH successfully enroled patients with cerebral oedema after acute intracerebral haemorrhage to assess the feasibility and safety of intravenous mannitol. The trial is novel with a dose-comparative approach with assessment of single and repeated mannitol dosing regimens, addressing an important gap in clinical practice.
KM 提取结果
0 个 Figure · 0 个 KM 面板